For research use only
| Cat No. | ABC-TC537S |
| Product Type | Human Melanoma Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Groin Lymph Node |
| Disease | Melanoma |
| Product Code | IGR 1; IGR1 |
IGR-1 human melanoma cells from 42-year-old male show epithelial morphology, BRAF and RAC1 mutations, adherent growth, key for melanoma progression.
IGR-1 is a human melanoma cell line derived from the inguinal lymph node metastasis of a 42-year-old male patient. The cell line exhibits epithelial-like morphology with adherent growth properties, forming tightly connected monolayers in culture. Genetically, IGR-1 carries oncogenic mutations including BRAF p. Val600Lys and RAC1 p. Pro29Ser, which are key drivers in melanoma pathogenesis and contribute to tumor progression. Cytogenetic analysis confirms the presence of these mutations, reflecting the cell line’s aggressive phenotype. Gene expression profiling indicates dysregulation of signaling pathways downstream of mutated BRAF and RAC1, promoting increased proliferation, migration, and survival. Together, these features make IGR-1 a relevant model for studying melanoma biology and evaluating targeted therapies against BRAF- and RAC1-driven oncogenic signaling.
| Product Code | IGR 1; IGR1 |
| Species | Human |
| Cat.No | ABC-TC537S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Groin Lymph Node |
| Disease | Melanoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Melanoma Cell Lines |
The IGR-1 cell line plays a pivotal role in advancing the understanding of human melanoma biology, particularly in the context of oncogenic signaling, metabolic regulation, and cell proliferation mechanisms. It is widely used to investigate the molecular pathways driven by BRAF and RAC1 mutation, supporting preclinical studies aimed at identifying novel therapeutic targets. Additionally, IGR-1 contributes to crucial insights into melanoma research, researchers could explore drug resistance and evaluate the efficacy of potential therapeutic interventions in melanoma, contributing to the development of more effective treatment strategies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Liao Y, Jia X, Ren Y, et al. Suppressive role of microRNA-130b-3p in ferroptosis in melanoma cells correlates with DKK1 inhibition and Nrf2-HO-1 pathway activation. Hum Cell. 2021;34(5):1532-1544. doi:10.1007/s13577-021-00557-5
Gill JG, Leef SN, Ramesh V, et al. A Short Isoform of Spermatogenic Enzyme GAPDHS Functions as a Metabolic Switch and Limits Metastasis in Melanoma. Cancer Res. 2022;82(7):1251-1266. doi:10.1158/0008-5472.CAN-21-2062
